Advances in Laboratory Diagnosis of Coronavirus Infections in Cattle.

Coronaviruses cause infections in humans and diverse species of animals and birds with a global distribution. Bovine coronavirus (BCoV) produces predominantly two forms of disease in cattle: a respiratory form and a gastrointestinal form. All age groups of cattle are affected by the respiratory form of coronavirus, whereas the gastroenteric form causes neonatal diarrhea or calf scours in young cattle and winter dysentery in adult cattle.

Measurement method for objective cyclist behavior parameters.

The objective of this research is to study the feasibility of measuring behavioral indicators that reflect effects of infrastructure and interaction with other road users. An observation study was performed using 6 cameras above a separated cycle path next to a road which included a crossing with both cyclists and cars. A learning method based on Single Shot MultiBox Detector was applied to automatically detect the cyclists, and cyclist tracks were determined.

Animal models for neonatal diseases in humans.

The development of vaccines for infants and young children requires the use of animal models at various stages of preclinical development. Animal models are being used to assess the quantity and quality of the immune response, onset and duration of the response, induction of systemic versus local immunity, protection against challenge infection for the assessment of vaccine efficacy, as well as safety and toxicity of the vaccine formulation itself. A variety of animal models are available, each with its own specific advantages and disadvantages.

CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.

Vaccines consisting of subunit or protein antigens are less immunogenic than traditional vaccines, and therefore require formulation with an adjuvant. Conventional adjuvants, however, often cause undesirable injection site reactions and Th2-biased immune responses. Therefore, novel vaccine adjuvants which can safely enhance and selectively bias the resulting immune response are required.